Stephen J. Freedland, MD, discussed an analysis real-world patients with metastatic castration-resistant prostate cancer, which he presented at the 2020 Genitourinary Cancers Symposium.
Stephen J. Freedland, MD, Warschaw Robertson Law Families Chair in Prostate Cancer director, Center for Integrated Research in Cancer and Lifestyle, co-directed, Cancer Genetics and Prevention Program, associate director, Faculty Development Samuel Oschin Comprehensive Cancer Institute, and professor of Surgery, at Cedar Sinai Medical Center, provided background on an analysis pf real-world patients with metastatic castration-resistant prostate cancer (mCRPC), which he presented at the 2020 Genitourinary Cancers Symposium (GU 2020).
Multiple phase III studies have shown that enzalutamide is a novel therapy for mCRPC. One of the questions that have come out of these clinical trials is, how does the efficacy translate in real-world patients. To answer this question, Freeland et al conducted a real-world analysis of prostate-specific antigen (PSA) outcomes among patients with mCRPC treated with enzalutamide.
For the analysis, the investigator reviewed data from nearly 1,000 male patients, using a medical record system that is used by about 30% of urologists in the United States. The patients who were included in the analysis had been treated before the approval of enzalutamide in mCRPC.
The results were similar to what was observed in the phase II PREVAIL trial (NCT01212991), says Freedland, with the median PSA being 58% and about 14% of patients reaching an undetectable PSA level.